Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models
Open accessThe DOI matches its Crossref record; 164 of the 168 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a challenging clinical event in medicine, particularly because of its ability to present with a variety of phenotypes including that of autoimmune hepatitis or other immune mediated liver injuries. Limited diagnostic and therapeutic tools are available, mostly because its pathogenesis has remained poorly understood for decades. The recent scientific and technological advancements in genomics and immunology are paving the way for a better understanding of the molecular aspects of DILI. This review provides an updated overview of the genetic predisposition and immunological mechanisms behind the pathogenesis of DILI and presents the state-of-the-art experimental models to study DILI at the pre-clinical level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reinforcing their well-established role in modeling immune–driven liver damage (Chakraborty et al., 2015; Gerussi et al., 2021).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Gerussi et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune-mediated DILI is related to the pharmacodynamic properties of the drug rather than direct or idiosyncratic liver injury, is not dose-related, but partially predictable, and arises when the host immune system leads to liver injury following medication administration.[3,5]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Immune checkpoints are physiological molecules fundamental in the negative control of immune response, acting as minimizer or even suppressor of immune activity, in order to avoid potential tissue damage from aberrant inflammatory response [103].”
BackgroundJaneway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472 · cited 1×
“A proto-typical example of drug-induced sterile inflammation is that occurring in APAP-DILI; in this scenario, inflammation can be inhibited by neutralization of HMGB1, one of the DAMPs released by hepatocytes [14,21,27].”
BackgroundRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
“In contrast to the original peptide, these altered peptides may have altered MHC molecule binding affinities (Adair, Meng, and Naisbitt 2021; Gerussi et al. 2021; Pichler 2013).”
BackgroundInfluentialPreclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Self-citationChallenges and Future of Drug-Induced Liver Injury Research—Laboratory Tests
Weber, S., & Gerbes, A. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116049 · Cited by 67
“However, PHHs show high phenotypic variability and instability regarding phenotypic characteristics in in vitro cultures, while liver cell lines are derived from liver cancer cells and therefore lack physiological drug-metabolizing enzymes and transporters limiting the representativeness of normal cellular toxic respo…”
BackgroundMechanisms of drug induced liver injury
Skat‐Rørdam, J., Lykkesfeldt, J., Gluud, L. L., & Tveden‐Nyborg, P. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05744-3 · Cited by 69
“This is in contrast to amoxicillin-clavulanate DILI where immune activation is generally believed to be a dete-riorative response further aggravating cell death [ 113 ].”
Endoplasmic Reticulum Stress and Mitochondrial Stress in Drug-Induced Liver Injury
Pu, S., Pan, Y., Zhang, Q., You, T., Yue, T., Zhang, Y., & Wang, M. (2023) · Molecules · doi:10.3390/molecules28073160 · Cited by 63
Insights into medication-induced liver injury: Understanding and management strategies
Tiwari, V., Shandily, S., Albert, J., Mishra, V. K., Dikkatwar, M. S., Singh, R. M., Sah, S. K., & Chand, S. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101976 · Cited by 61
“Large studies have reported DILI mortality rates of approximately 5 – 10 %, with liver transplantation often considered when symptoms progress to acute liver failure (ALF) [113].”
Sex disparity and drug-induced liver injury
Floreani, A., Bizzaro, D., Shalaby, S., Taliani, G., & Burra, P. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.06.025 · Cited by 46
Baker, T. K., Vleet, T. R. V., Mahalingaiah, P. K. S., Grandhi, T. S. P., Evers, R., Ekert, J. E., Gosset, J. R., Chacko, S. A., & Kopec, A. K. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001510 · Cited by 42
Li, Q., Chen, F., & Wang, F. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00921-4 · Cited by 41
“their metabolites covalently bind to proteins in the body to form drug/metabolite-protein adducts that can be processed by antigen-presenting cells as semi-antigens and then recognized by T cells to induce immune responses that may have a genetic or even metabolic basis, with dendritic cells acting as antigen-presenti…”
BackgroundHuman Three-Dimensional Hepatic Models: Cell Type Variety and Corresponding Applications
Xu, Q. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.730008 · Cited by 39
“Genetic polymorphism, especially singlenucleotide polymorphism (SNP), is related to interindividual differences in CYP metabolism capacity and immune-mediated drug responsiveness (Ingelman-Sundberg, 2001; Gerussi et al., 2021).”
BackgroundMethodImpact of Pharmacogenomics in Clinical Practice
Principi, N., Petropulacos, K., & Esposito, S. (2023) · Pharmaceuticals · doi:10.3390/ph16111596 · Cited by 33
“This is the case of acute liver failure [77] and the most severe drug reactions, such as SJS, TEN, DRESS, and maculopapular exanthema (MPE) [78].”
BackgroundSingh, D., Khan, M. A., & Siddique, H. R. (2023) · Phytotherapy Research · doi:10.1002/ptr.8022 · Cited by 39
“Furthermore, evidence indicates that the host's adaptive immune system, primarily influenced by HLA polymorphism, and other factors affecting the presentation of hapten peptides or neoantigens are critical in developing idiosyncratic DILI (Gerussi et al., 2021).”
BackgroundAcute-on-chronic liver failure: pathophysiological mechanisms and clinical management
Sarin, S. K., Choudhury, A. K., Kumar, A., Mahmud, N., Lee, G. H., Ning, Q., Tan, S.-S., Thanapirom, K., Arora, V., Nakayama, N., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01159-4 · Cited by 39
Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury
Tao, W., Fan, Q., & Wei, J. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46020078 · Cited by 30
“Several antibiotics like amoxicillin-clavulanate, cephalosporins, fluoroquinolones, and macrolides may induce idiosyncratic liver toxicity [12].”
BackgroundTeschke, R., & Danan, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310855 · Cited by 29
Applications of In Silico Models to Predict Drug-Induced Liver Injury
Lin, J., Li, M., Mak, W. Y., Shi, Y., Zhu, X., Tang, Z., He, Q., & Xiang, X. (2022) · Toxics · doi:10.3390/toxics10120788 · Cited by 25
“Hepatic inflammation is the common manifestation of many liver diseases, including drug-induced hepatotoxicity [47].”
Liver disorders and phytotherapy
Qadri, S. S., Javaid, D., Reyaz, A., Ganie, S. Y., & Reshi, M. S. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102047 · Cited by 32
Cui, G., Abe, S., Kato, R., & Ikuta, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349184 · Cited by 25
Drug-Induced Liver Injury—Pharmacological Spectrum Among Children
Maris, B. R., Grama, A., & Pop, T. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052006 · Cited by 25
“Its idiosyncratic subtype is responsible for about 10% of ALF cases in the United States, surpassing viral hepatitis [2–4].”
Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?
Christen, U., & Hintermann, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898615 · Cited by 19
“One has to consider here that the liver otherwise would be prone to autoimmunity due to the constant exposure to drugs and xenobiotics that might result in immune-mediated drug-induced liver injury (DILI) (14).”
BackgroundEzhilarasan, D., Harini, K. S., Karthick, M., & Selvaraj, C. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14369 · Cited by 17
“It is the most classic example of an intrinsic DILI and it causes predictive hepatotoxicity in individuals who consume high doses (Gerussi et al., 2021).”
BackgroundTeschke, R., & Danan, G. (2024) · Medicines · doi:10.3390/medicines11040009 · Cited by 17
Teschke, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076663 · Cited by 16
Yang, H., Han, J. W., Lee, J. J., Lee, A., Cho, S. W., Rho, P. R., Kang, M., Jang, J. W., Jung, E. S., Choi, J. Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138112 · Cited by 17
Human Liver Organoid Models for Assessment of Drug Toxicity at the Preclinical Stage
Karabicici, M., Akbari, S., Ertem, Ö., Gümüştekin, M., & Erdal, E. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230411100121 · Cited by 12
Abdellaoui-Soussi, F. E., Brusilovsky, M., Buck, E., Bacon, W. C., Dadgar, S., Fullerton, A. M., Durban, V. M., Barrile, R., Helmrath, M. A., Takebe, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202508584 · Cited by 16
Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety
Jadalannagari, S., & Ewart, L. C. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2328794 · Cited by 15
“Indirect DILI is being increasingly recognized as mechanistically associated with the pharmacodynamic properties of the drug candidate, with cited examples involving the adaptive immune system [10].”
Perspectives of data science in preclinical safety assessment
Steger‐Hartmann, T., Kreuchwig, A., Wang, K., Birzele, F., Draganov, D. I., Gaudio, S., & Rothfuß, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103642 · Cited by 12
Seo, S., Lee, J., Ham, D.-W., & Shin, E. (2024) · Parasites Hosts and Diseases · doi:10.3347/phd.23129 · Cited by 11
Zhao, J.-W., Zhao, W., Zhao, M., & Lu, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1499697 · Cited by 13
“…Gerussi et al. suggested that the host adaptive immune system is primarily influenced by factors such as HLA polymorphisms, which affect the presentation of hapten peptides or novel antigens and play a critical role in the occurrence and development of specific DILI (49) (as shown in Figure 2).”
Roser, L. A., Luckhardt, S., Ziegler, N., Thomas, D., Wagner, P. V., Damm, G., Scheffschick, A., Hewitt, P. G., Parnham, M. J., & Schiffmann, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275368 · Cited by 12
IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept
Roser, L. A., Sakellariou, C. A., Lindstedt, M., Neuhaus, V., Dehmel, S., Sommer, C., Raasch, M., Flandre, T., Roesener, S., Hewitt, P. G., et al. (2024) · Journal of Immunotoxicology · doi:10.1080/1547691x.2024.2332177 · Cited by 10
“It presents the most frequent DILI subtype, is dose-dependent, and predictable in animals as it is induced by compounds with immanent hepatotoxic effects, such acetaminophen (Gerussi et al. 2021).”
Brecklinghaus, T., Albrecht, W., Duda, J., Kappenberg, F., Gründler, L., Edlund, K., Marchan, R., Ghallab, A., Cadenas, C., Rieck, A., et al. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.08.006 · Cited by 11
Drug-induced liver injury: Diagnosis, management and the role of liver transplantation
Ozturk, N. B., Uskudar, E., Toruner, M. D., Simsek, C., & Gurakar, A. (2025) · Hepatology Forum · doi:10.14744/hf.2024.2024.0003 · Cited by 9
Villanueva-Bádenas, E., Donato, M. T., & Tolosa, L. (2023) · Antioxidants · doi:10.3390/antiox12071315 · Cited by 11
“On the other hand, innate immunity can be triggered by DAMPs released by damaged hepatocytes, causing inflammation [36].”
BackgroundThe progression of chronicity and autoimmune hepatitis in recurrent drug-induced liver injury
He, T., Ren, L., Gong, M., Guo, Y., Wang, L., Xiao, X., Wang, R., & Bai, Z. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102009 · Cited by 8
Yang, Y., Chen, Q., Liu, Z., Huang, T., Hong, Y., Li, N., Ai, K., & Huang, Q. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.08.239 · Cited by 7
Ma, D., Liu, X., Ai, G., Pan, W. Q., Liu, L., Huang, Y., Liao, Y., Lu, Y., Zhang, Z., Zhou, H., et al. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1377333 · Cited by 10
Newly identified genetic variants associated with idiosyncratic drug-induced liver injury
Stolz, A. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000822 · Cited by 7
Xiong, Y.-T., Wang, J.-F., Li, L., Bai, Z.-F., Liu, Y., Huang, A., Wang, K.-X., Fu, Y., Yang, W., Guo, C., et al. (2024) · iLIVER · doi:10.1016/j.iliver.2024.100095 · Cited by 6
Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
Cheng, Y., Chang, W., Yen, H., Peng, Y., Chang, W., & Chang, P. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14556 · Cited by 6
“Effector CD4+ T cells can orchestrate an immune response by upregulating membrane costimulatory molecules, producing cytokines and killing target cells via the membranous molecules.(16) Drug-triggered effector CD8+ and CD4+ T cells play an important role in DILI.”
BackgroundAutoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
Xiong, Y., Wang, J., Niu, X.-X., Fu, Y., Wang, K., Wang, C., Li, Q., Wang, J., Zhao, J., & Ji, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1071709 · Cited by 7
“Damage-associated molecular patterns (DAMPs) released by druginjured hepatocytes activate innate immunity and lead to sterile inflammation, which further amplifies tissue damage (Mosedale and Watkins, 2017; Gerussi et al., 2021).”
BackgroundThe native liver as inspiration to create superior in vitro hepatic models
Carpentier, N., Urbani, L., Dubruel, P., & Vlierberghe, S. V. (2023) · Biomaterials Science · doi:10.1039/d2bm01646j · Cited by 7
Liu, X., & Fan, F. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1731947 · Cited by 4
“Mice demonstrated the strongest signal for immune-mediated hepatitis (LR+ = 462.4), reinforcing their well-established role in modeling immune–driven liver damage (Chakraborty et al., 2015; Gerussi et al., 2021).”
InfluentialInsights into the Biochemical and Immune Mechanisms in Drug-Induced Liver Injury Pathogenesis
Saville, E., Wells, G., Farrell, L., Naisbitt, D. J., & Meng, X. (2026) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00530 · Cited by 5
Puri, M. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4020012 · Cited by 5
“Single-cell analysis in DILI, illustrated in Figure 3B, shows a growing trend of macrophages, which could be due to their activated role, often associated as pro-inflammatory in the DILI disease model [36].”
Wu, H., Yan, W., Liu, K., Jing, J., & Ye, W. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102472 · Cited by 4
Acute Hepatitis with Positive Autoantibodies: A Case of Natalizumab-Induced Early-Onset Liver Injury
Cunha‐Silva, M., de Moraes, P. B. S., de Carvalho, P. R., da Costa, L. B. E., Assis‐Mendonça, G. R., Lalli, C. A., Fernandes, G. C. A., Monteiro, F. B., Lamas, G. M., Damasceno, A., et al. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.936318 · Cited by 4
“The detection of positive autoantibodies in patients with DILI is not uncommon and has been described with several drugs, including nitrofurantoin, hydralazine, alpha-methyldopa, and amoxicillin/clavulanate [8,9].”
Borlak, J. T., & Spanel, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125899 · Cited by 4
“A recent review summarized some of the molecular events involved in immune-mediated drug-induced liver injury [32].”
EFFICACY AND SAFETY OF HERBAL MEDICINES IN ASIA
Baihaqi, A. A., & Levita, J. (2021) · Jurnal Ilmiah Farmako Bahari · doi:10.52434/jfb.v12i2.1244 · Cited by 4
Autoimmune Hepatitis (AIH) Related to Drug-Induced Liver Injury (DILI) Due to Atorvastatin
Loeza-Suárez, J., García-Luna, D. C., Hernández-Mirón, J., Ramírez-Marcial, R., & Valero-Gaona, G. A. (2025) · Cureus · doi:10.7759/cureus.82315 · Cited by 3
“DILI is characterized by liver injury detected through elevated liver enzymes in the blood, which may be associated with a specific drug [9].”
InfluentialRecent Progress in Small Molecule Fluorescent Probes for Imaging and Diagnosis of Liver Injury
Liu, S., Huang, F., Huang, X., Zhang, F., Pei, D., Zhang, J., & Hai, J. (2025) · Targets · doi:10.3390/targets3020018 · Cited by 3
Clarke, E., Gardner, J., Howsawi, A., Gillgrass, L., Roehmel, J. F., Whitaker, P., Tachtatzis, P., Cratchley, A. L., Peckham, D. G., & Naisbitt, D. J. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.11.011 · Cited by 2
Frolli, A., Parvis, G. E., Bullo, M., Grano, S., Fornari, G., Bonuomo, V., Cilloni, D., & Fava, C. (2025) · Hematology Reports · doi:10.3390/hematolrep17060069 · Cited by 2
“Ibrutinib modulates several immune pathways, including T-cell receptor signaling and cytokine release [17,18].”
MOTS-c Protects Against Acetaminophen-induced Liver Injury through the MAPK Signaling Pathway
Li, N., Xu, Y., Chen, Q., Jiang, J. R., & Li, W. W. (2026) · Protein and Peptide Letters · doi:10.2174/0109298665430028251230103831 · Cited by 2
Drug-induced autoimmune hepatitis due to atorvastatin: a complex clinical case and literature review
Serrano-Pérez, N. H., Rodriguez-Martinez, J. S., Feria-Agudelo, S. M., Morales-Leyte, A. L., & Córdova‐Gallardo, J. (2026) · Gastroenterology report · doi:10.1093/gastro/goag022 · Cited by 2
Drug-induced multisystem syndromes: An overlooked challenge in pharmacovigilance
Rai, U. U., Haneef, M., Kosey, S., & Sood, R. (2026) · International Journal of Risk & Safety in Medicine · doi:10.1177/09246479261458062 · Cited by 2
Akbar, S. M. F., & Mamun-Al-Mahtab, M.-A.-M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00002-x · Cited by 2
Pathophysiological Differences and Differential Diagnosis of Autoimmune and Drug-Induced Hepatitis
Zeni, N., Cristofani, A., Piano, S. S., Bolognesi, M., & Romano, A. (2025) · Livers · doi:10.3390/livers5020022 · Cited by 2
“Several methods for the preliminary assessing of the causality of DILI have been developed [99,100].”
Philips, C. A., Theruvath, A. H., & Ravindran, R. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247867 · Cited by 2
Tan, K., Yang, W., Pang, L., & Hou, F.-Q. (2022) · Medicine · doi:10.1097/md.0000000000029909 · Cited by 3
“Not knowing the CHM composition will affect a clinician’s diagnosis of DILI, which is not conducive to the clinical study of CHM-DILI.”
BackgroundInfluentialCueto‐Sánchez, A., Zeo-Sánchez, D. E. D., Segovia‐Zafra, A., Matilla‐Cabello, G., Bodoque-García, A., Lucena, M. I., & Paz, M. V. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00018 · Cited by 1
Modulating the Gut Microbiota to Combat Drug-Induced Liver Injury: A New Frontier in Hepatic Health
Ye, Y., & Chu, H. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009178 · Cited by 1
Shibata, M., Uchida, N., Ooka, A., Shizu, R., & Yoshinari, K. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2025.101505 · Cited by 1
Review on clinical diagnosis, pathogenesis and therapeutic strategies of drug-induced liver injury
Tan, X., Gao, J., & Wang, C. (2025) · Journal of Holistic Integrative Pharmacy · doi:10.1016/j.jhip.2025.09.002 · Cited by 2
Multi-lineage hepatic organoids reveal toxic exosome mediated indirect hepatotoxicity
Sun, L., Zhang, Y., Niu, Y., Yang, H., Zhou, L., Jia, X., Chen, Y., Liu, Z., Wang, T., Liang, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69548-0 · Cited by 2
“For instance, diclofenac causes severe liver injury only in a subset of patients 6,7 .”
A Case of Severe Ibrutinib‐Induced Liver Injury and Successful Transition to Acalabrutinib
Ciornolutchii, V., & Ismaiel, A. (2026) · Liver International · doi:10.1111/liv.70573 · Cited by 1
Alberola, I. D., Zeo-Sánchez, D. E. D., Garrido‐Rodríguez, V., Gomez, C. L., Rodriguez‐Diaz, C., Andrade, R. J., Lucena, M. I., Paz, M. V., & García‐Fuentes, E. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.014 · Cited by 1
Self-citationde Andrade, J. G., de Oliveira, A. R. L., Calumby, B. S. A., Alves, G. G. D. F., de Melo, A. K. G., Braz, A. D. S., & Soares, M. R. M. P. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07988-6 · Cited by 1
“These immunological pathways have been proposed as central mechanisms underlying autoim-mune-like features DILI [14].”
Buchalter, J., O'Donovan, H. C., Jordan, E., Galvin, Z., & Walshe, J. M. (2026) · Case Reports in Oncological Medicine · doi:10.1155/crom/2417755 · Cited by 1
“Immunotherapeutic agents, including biologics, and in particular immune checkpoint inhibitors for advanced cancer, are associated with immune-mediated adverse reactions, including liver injury [17].”
Chen, Z., Zhang, J., Chen, W., Chen, X., Lu, D., & Li, J. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17110-5 · Cited by 1
“14,15 We speculate that the elevated ALT values in the participants receiving neoadjuvant chemotherapy in combination with targeted therapy may have been due to pharmacologic liver injury.”
Osman, E. Y., Abo-Elnasr, S. E., Zaher, S. M., & AbuoHashish, N. A. (2021) · Research Square · doi:10.21203/rs.3.rs-990751/v1 · Cited by 1
“This results in activation of liver immune cells, including Kupffer cells, natural killer lymphocytes and dendritic cells thus which triggers an in�ammatory cascade involving recruitment of neutrophils and monocyte from blood [42].”
Bioengineering hepatic organoids: Development of an alternative model for liver toxicity
Bouwmeester, M. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2054
Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury
Sethi, N., Khokhar, M., Mathur, M., Batra, Y., Mohandas, A., Tomo, S., Rao, M., & Banerjee, M. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1791559 · Cited by 3
“85 The contributionof both theinnate and adaptive immune systems is essential.”
Pudgerd, A., Pluangnooch, P., Soontrapa, K., Saedan, S., Vanichviriyakit, R., & Sridurongrit, S. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42691
“Immune-mediated hepatocellular injury is a crucial step in the development of liver diseases [11,12].”
Hepatic Nonparenchymal Cells and Liver-Associated Lymphoid Cells
Gardner, C. R., Laskin, J. D., & Laskin, D. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00250-3
Цубанова, Н. А., Волощук, Н. І., & Galevich, G. B. (2025) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2025-29(2)-05
Liu, W., Zhang, Z., Ma, X., Zeng, X., Yuan, S., Li, X., Nie, F., & Yang, L. (2025) · Medicine · doi:10.1097/md.0000000000045750
“[12] Multiple studies have shown that the prevalence of DILI does not differ between males and females, whereas AIH predominantly affects females, particularly postmenopausal women, [13– 15] consistent with the findings of this study.”
Hadi, S., Setiawan, D., Viogenta, P., Khairunnisa, A., & Nastiti, K. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00833
Alanzi, T. S. K., Alghuraydh, H. I. A., Alsalmi, A. T. Z., Aljohani, K. S. A., AlJuhani, A. I. H., Alsaif Salem Abdulaziz, S., Alshehri, A. M. A., Alanazi, O. S. O., & Alraweli, A. M. O. (2024) · International Journal of Computational and Experimental Science and Engineering · doi:10.22399/ijcesen.5138
Li, Q., Lin, Y., Zeng, X., Zhou, L., Wang, F., Ye, Q., Gao, Y., Guo, L. L., Zhu, J., Li, J., et al. (2026) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848261440777
“21,22 Glucocorticoids can inhibit the immune response and reduce the production of pro-inflammatory cytokines, which are beneficial for protecting hepatocytes from further damage and mitigating inflammatory responses.”
Salman, I. N., Jabbar, R. K., Emad, I., Hassan, Z. A. A., Harbi, A. M., Khudhair, A. Y., Hussein, M. A. M., Hamid, A. M., Amir, M. A. A., Ali, M. W., et al. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70268
Mad-adam, N., Kyaw, H. A., Poonsawaeng, I., Ketsawatsomkron, P., Bunbamrung, N., Pittayakhajonwut, P., Thawai, C., & Muta, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.10.750749
Herb-induced liver injury: An immunological perspective
Liang, S., Wang, S. H., Li, Y., & Rao, T. (2026) · Toxicology · doi:10.1016/j.tox.2026.154594
Yang, Y., Liu, B., Cao, Z., Fang, H., Guo, Y., Jiang, T., Lü, Y., 曲, 淑., Tang, Q., Wang, Y., et al. (2026) · Metabolites · doi:10.3390/metabo16100733
“The occurrence of drug-induced liver injury is strongly associated with abnormal activation of the immune system [11].”
Rahangdale, K., Mehtani, R., Nandi, B., Dinda, A. K., Nair, S. V., & Vyas, A. K. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124724
Metadata
- Authors
- Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P.
- Affiliations
- Azienda Ospedaliera San Gerardo (IT)
- Institute of Molecular Biology and Pathology (IT)
- Université Libre de Bruxelles (BE)
- Institute of Molecular Biology and Pathology (IBPM), National Research Council of Italy (CNR), 00185 Rome, Italy
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29016 Málaga, Spain
- Corresponding author
- Gerussi, Alessio
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-27
- Volume
- 22
- Issue
- 9
- Pages
- 4557
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8123708
- OpenAlex
- W3159227089
- Cited by
- 87
- References
- 168
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 15 · 2023: 16 · 2022: 12 · 2021: 4
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- American Medical Association Foundation
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, immunogenetics, genetic susceptibility, autoimmune hepatitis, immune-mediated liver injury, pathogenesis, animal models
- MeSH terms
- Humans, Immunogenetics, Liver, Models, Theoretical, Phenotype, Risk Factors, Hepatitis, Autoimmune, Genetic Predisposition to Disease, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
